Pulmonary metastasectomy is nowadays a common practice in thoracic surgery. Clinical prognostic markers for poor outcome after pulmonary metastasectomy have been proposed in the late 1970's of the last century. Despite new insights in molecular mechanisms and advances in imaging techniques, neither molecular markers nor radiological features of metastases are used as prognosticators in routine clinical practice. Biomarkers associated with aggressive tumour behaviour came into the focus of clinical research and are the basis of personalized medicine. In addition, non-invasive imaging modalities like positron emission tomography and high-resolution computed tomography can provide further information on tumour aggressiveness. Regardless of a myriad of studies assessing prognostic markers in primary tumours, little is known about these markers in metastatic lesions. Furthermore, it has been emphasized that tumour biology of the primary might not reflect the behaviour of the corresponding metastasis. Therefore, information on the biology of metastases is necessary to treat patients adequately. This work reviews potential prognostic biomarkers in patients with pulmonary metastases, grouped in soluble tumour markers, tumour suppressor genes/proto-oncogenes and proteins involved in cell adhesion, tumour growth, cell metabolism and tumour angiogenesis.
INTRODUCTION
Since the first case report on a surgically removed pulmonary nodule by Weinlechner [1] in 1882, pulmonary metastasectomy has evolved into a standard procedure in patients with lung metastases. Widely accepted selection criteria are (i) a controlled or controllable primary tumour, (ii) the absence of extrathoracic metastases, (iii) the patient must be able to tolerate the degree of the planned lung resection and (iv) the non-availability of another superior effective therapy [2] .
Although resection of pulmonary metastases is routinely performed in a variety of primary tumours, little is known on prognostic factors influencing the outcome of pulmonary metastasectomy. In times of individualized patient treatment, this knowledge is of great importance. Patients with a high risk of early tumour recurrence might benefit from pseudoadjuvant chemotherapy regimens. On the contrary, surveillance strategies may be sufficient for intermediate or low-risk patients. Moreover, a mapping of prognostic factors might help in the decision-making process when offering patients a remetastasectomy. A localized removal of pulmonary nodules is not recommendable if a recurrence within weeks is expected. Important clinical prognostic factors have been proposed by the International Registry of Lung Metastases (IRLM) including a short disease-free interval, multiple pulmonary nodules and an incomplete surgical resection [3] . However, contradicting studies can be found for other well-established clinical markers in regard to their prognostic impact after pulmonary metastasectomy [4, 5] . Thus, factors reflecting the tumour biology might be more accurate in defining the prognosis of patients with pulmonary tumour spread [6] . This review focuses on the prognostic markers predicting the clinical outcome in patients undergoing pulmonary metastasectomy that can be identified by molecular biological and radiological methods.
Using tissue or body fluid samples of patients to predict the individual risk of a certain disease or the success of a therapeutic approach has nowadays become routine in many diseases. In addition, biological markers are also of prognostic value in the course of some diseases [7] . The quest for reliable biomarkers is an important field of today's research in general and cancer research in particular. Compared with the bulk of literature regarding markers in primary tumours, little data are available on biological markers in pulmonary metastasectomy. Currently, evidence in literature is mostly based on small series of patients with primary colorectal carcinoma (CRC), melanoma and sarcoma.
In order to provide a clear overview, reviewed markers will be grouped into soluble tumour markers, cell adhesion, tumour growth, tumour suppressor genes/proto-oncogenes, cell metabolism and tumour angiogenesis (Fig. 1) .
purposes in the follow-up of patients with malignant disease. Some soluble factors have also been proposed to be capable of predicting the outcome of patients undergoing pulmonary metastasectomy.
Carcinoembryonic antigen.
A heightened level of carcinoembryonic antigen (CEA) can be detected in patients with several types of cancer, inter alia CRC. Regarding its prognostic value in pulmonary metastasectomy, several contradicting studies with small sample sizes have been performed [4, 5] . Recently, two large studies including 1030 and 1112 patients confirmed the prognostic value of increased prethoracotomy CEA level (cut-off value >5 ng/ml) for 5-year survival in multivariate analysis [8, 9] . CEA expression persists during the metastatic process and has been identified in 93.3% of pulmonary metastases of CRC by immunohistochemistry [10] . Hence, it poses a helpful parameter in detecting the recurrence of disease.
CA19-9, alpha-fetoprotein and human chorionic gonadotropin. CA19-9 could be identified in 75% of pulmonary metastases and in 73.3% of paired primary CRC with high concordance in a work by Kayser et al. However, it did not influence the outcome [10] . Increased levels of alpha-fetoprotein (AFP; cut-off value ≥500 ng/ml), a marker associated with hepatocellular carcinoma (HCC), have been described as a negative prognostic factor for survival in patients undergoing resection for pulmonary nodules from HCC [11, 12] . These findings were confirmed by Kuo et al. [13] , who found a significant association of high AFP and worse disease-free survival applying a cut-off value of 100 ng/ml. Although sample sizes of these three studies are small, they emphasize the potential value of serum markers to predict the postoperative outcome of patients following pulmonary metastasectomy. Besides AFP, des-gamma-carboxy prothrombin (DCP) is an established serum marker to monitor tumour burden and recurrence in patients with primary HCC. Kitano et al. [14] demonstrated a prognostic effect of DCP in their study population of 45 patients undergoing pulmonary metastasectomy from primary HCC (cut-off value: 40 mAU/ml) in univariate analyses regarding the disease-free survival and the overall survival. In germ cell tumours AFP and human chorionic gonadotropin (hCG) are accepted tumour markers. Elevated prethoracotomy serum levels of either AFP (cut-off value >15 μg/l) or hCG (cut-off value >5 Units/l) were significantly associated with reduced 5-year survival (50 vs 87.2 months) in patients with pulmonary spread of primary germ cell tumours [15] .
Cell adhesion
The role of cell adhesion in cancer was first described in 1914 by Boveri. Since that time, the attention of metastasis research was drawn to molecules mediating cell-cell and cell-matrix adhesion [16] . Cell-adhesion molecules (CAMs) are capable of initiating intracellular signalling and play a key role in epithelialmesenchymal transition, which is a key mechanism in the metastasic cascade [17] . Loss of cell adhesion can be determined by demonstrating the presence of invasion of other structures with light microscopy. Shiono et al. demonstrated in pulmonary metastases from primary CRC that vascular invasion as well as intra-alveolar cancer cell clusters was associated with diminished prognosis after pulmonary metastasectomy in multivariate analysis (39.9 vs 85.8%; 46.9 vs 88.2%, respectively), and the presence of 10 or more of such infiltrative cell clusters predicted early local recurrence. Supporting this, lymphatic and pleural invasion were further variables with significant impact on 5-year survival in univariate analysis (47.0 vs 78.4 months; 49.5 vs 63.5 months) [18, 19] . Expression of membrane-bound adhesion molecules like cadherins, immunoglobulin-like CAMs (Ig-CAMs), CD44 and integrins can be determined by the utilization of immunohistochemistry.
Expression of cadherins. E( pithelial)-cadherin is one of the most extensively studied member of the cadherin-family. It mediates cell-cell adhesion, and thus its down-regulation plays a pivotal role in tumour dissemination [20] . In patients undergoing pulmonary metastasectomy subsequent to primary CRC, reduced expression of E-cadherin in resected nodules was an independent predictor for poor survival (5-year survival 74.5 vs 23.9 months). Loss of beta-catenin, which binds to E-cadherin at the intracellular side of the cell membrane, was also associated with worse 5-year survival in univariate analysis [21] .
Expression of immunoglobulin-like cell-adhesion molecules.
The expression of members of the Ig-CAM family was investigated in hepatoblastoma patients. Up-regulation of CEA-related CAM 1 (CEACAM1, also known as CD66a) predicted early metastasis to the lung and was associated with a decreased 5-year survival (92 vs 29%) [22] . CEACAM1 is also down-regulated in invasive HCC, however, data on expression levels in thoracic nodules and a possible prognostic value need to be elucidated [23] .
Expression of CD44. The standard isoform of CD44 is expressed by many cell types and mediates cell-matrix adherence by binding hyaluronic acid. As it is also a molecular marker for cancer stem cells, extensive research has been undertaken to understand the role of this family of proteins in tumour progression and metastasis [24, 25] . Different CD44 variants, which are the result of alternative splicing of the CD44 gene, are expressed in tumour tissue. The up-regulation of CD44 seems to play an important role in the homing of tumour cells to metastatic sites [25] . An increased expression of the CD44 gene in pulmonary metastases compared with corresponding primary CRC was found in a study by Kim et al. [26] . In a subsequent study, CD44 variant 9 expression was found in 88% of primary CRC with consecutive pulmonary dissemination, compared with 42% in patients without pulmonary dissemination. However, specimens from pulmonary nodules were not examined and follow-up after pulmonary dissemination was not described [27] . Additionally, an increased expression level of CD44 variant 6 in patients with primary CRC was related to a poor 2-year survival after pulmonary metastasectomy [28] .
Expression of integrins. Another group of proteins relevant to cell-matrix interaction are integrins. They consist of an alpha-and a beta-subunit and mediate their adhesive effect by binding fibronectin and laminin [29] . Integrin alpha v was found to be expressed in 85.7% of lung metastases from primary CRC and in 52.4% of the paired primary tumours [30] . Yet, no data on the post-metastasectomy follow-up were provided by this study.
Tumour growth
Sustained cell proliferation is the key characteristic of malignant tumours. It is a consequence of attributes described as the hallmarks of cancer by Hanahan and Weinberg [31] , such as resistance to cell death and up-regulation of proliferative signals. Proliferation can either be quantified by estimating the tumour growth radiologically or ex post by histological evaluation of the resected specimen.
Proliferation markers. Ki-67 (also known as MIB-1) is routinely used in histopathology to determine the proliferation rate of tumours. A high expression level at the primary tumour site was associated with pulmonary recurrence in osteosarcoma patients and mortality was increased in the strongly positive sub-group compared with patients with less proliferating osteosarcomas [32] . In contrast to that, a study on pulmonary metastases and matched primary osteosarcomas showed that Ki-67 expression did not correlate with the time to first pulmonary spreading. Follow-up until pulmonary recurrence after metastasectomy was not given and survival analysis dependent on Ki-67 was not described [33] . Besides, in patients with primary melanoma, the number of Ki-67 cells in the pulmonary nodules did not correlate with overall survival [34] . In patients with primary renal cell carcinoma (RCC) another marker for proliferation, the proliferating cell nuclear antigen (PCNA), was significantly higher in pulmonary metastases compared with primary tumours of patients with or without metastases. Moreover, mean PCNA expression was higher in patients with poor survival [35] . Though highly proliferating primary CRC was linked to tumour grade, lymphnode involvement, distant metastasis and an independent prognostic marker for 5-year survival in multivariate analysis, specific data after pulmonary metastasectomy are still lacking [36, 37] .
Tumour doubling time. Rapid tumour proliferation can also be estimated in vivo by imaging techniques, e.g. computed tomography (CT). The tumour doubling time (TDT), indicating aggressive tumour biology, can vary between different types of tumours, within the same histological entities and even within the same patient (e.g. with multiple metastases) [38] . In patients with pulmonary metastases from CRC, a TDT <100 days was predictive for early pulmonary recurrence. Additionally, the overall survival was decreased in this sub-group with rapidly growing metastases; however, statistical significance was not reached [39, 40] . In patients with primary soft-tissue sarcoma, the TDT examined by chest X-ray was not associated with the patients' outcome [41] . Using CT for surveillance of patients with primary soft-tissue sarcoma, two studies identified the TDT of pulmonary nodules as a poor prognostic marker for overall survival [42, 43] . Moreover, in a series of 39 patients with primary osteosarcoma, the TDT of the pulmonary nodule was also predictive of poor overall survival, whereas this finding was not supported by Nakamura et al. in a small series of 11 patients [42, 43] . Ollila et al. [44] could identify a TDT <60 days as a significant prognostic marker for poor survival after pulmonary metastasectomy from primary melanoma using chest X-ray. Subsequently, the prognostic value and the cut-off value at 60 days were confirmed by Lee et al. It is noteworthy that the proliferative index determined by immunohistochemical staining for Ki-67 did not correlate with the radiologically determined TDT in their patient cohort [34] .
Markers of apoptosis. As tumour growth is the result of cell division minus cell loss, antiapoptotic markers like bcl-2 or proteins involved in apoptosis (e.g. caspases) might provide additional information on the cell turnover. The presence of bcl-2 in pulmonary metastases correlated with worse overall survival in patients with primary CRC and was divergent from the expression in the corresponding primary tumour [10] . This negative correlation between bcl-2 expression and patients' prognosis could not be confirmed in a series of osteosarcoma patients. Neither the expression level in the primary nor in the pulmonary metastases had influence on the recurrence-free survival and overall survival [45] . Caspase-3, a marker for cell apoptosis, was assessed in pulmonary metastases from primary melanoma, but was shown to have no effect on the clinical outcome after pulmonary metastasectomy [34] (Tables 1 and 2 ).
Tumour suppressor genes/proto-oncogenes
In general, tumour suppressor genes encode proteins, which have repressive functions on the cell-cycle. Proto-oncogenes are cellular genes, which are titled as oncogenes as soon they are mutated, amplificated or rearranged, leading to up-regulated cell growth [46] . Genes are indicated by italic letters, whereas proteins are denoted by normal letters. Alterations fo DNA or protein levels might have a diverging clinical impact.
Expression of p53. One of the most extensively studied tumour suppressors is the TP53 gene, coding for the p53 protein, which plays an essential role in the cell-cycle arrest and apoptosis of damaged cells [47] . Kayser et al. found positive p53 protein staining in 26/60 pulmonary metastases and in 17/60 paired primary CRC, with a total of 45/60 concordant positive or negative stainings. Nevertheless, p53 expression was not associated with post-metastasectomy outcome [10] . Danner et al. compared chromosomal aberrations in the TP53 gene region in paired primary and metastatic tissue specimens from CRC. Gain mutations at 20q, which correlates with altered TP53, were evident in 70 and 54% of primary tumours and metastases, respectively. Furthermore, they could confirm the finding by Kayser et al., who found no significant correlation with recurrence-free survival after pulmonary metastasectomy or overall survival [48] . In patients with primary osteosarcoma, expression of p53 in the primary tissue failed to predict tumour progression [49] . However, in a more recent study including patients with pulmonary nodules from primary osteosarcoma, negative expression of p53 was significantly associated with poor survival after pulmonary metastasectomy in univariate analysis (3-year post-metastasectomy survival rate 17 vs 34%). It was concluded that the p53 might have a role as prognostic marker only in the subset of patients presenting with pulmonary dissemination [45] .
Chromosomal aberrations. SMAD2, SMAD4/DPC4 and DCC, other well-investigated tumour suppressor genes, are clustered on the chromosome arm 18q, and a loss of 18q is associated with tumourigenesis [50] . In CRC patients, a loss of 18q was evident in 86% of pulmonary metastases, compared with 70% in corresponding primary tumours. However, a significant relationship between the loss of 18q and the clinical outcome could not be established [48] .
K-ras mutation status. In CRC, mutations of the proto-oncogene k-ras, which encodes a small guanosine triphosphate-binding molecule involved in growth signalling pathways, are thought to be an early event in the progression from adenoma to carcinoma. However, only one-third of primary carcinomas have detectable alterations in this gene [46, 51] . K-ras mutation can more often be found in lung metastases (60%) than in liver metastases (33.3%). Additionally, in patients with k-ras mutation in the primary CRC, the lung is more often the initial site of metastasis compared with k-ras wild-type, thus k-ras might play an important role in metastatic dissemination, paticularly to the lung [52] [53] [54] . These findings were corroborated by data from the VICTOR study revealing that patients with k-ras mutation in the primary tumour have a significantly higher risk of lung relapse in multivariate analysis (hazard ratio: 1.9, 95% confidence interval: 1.1-3.1), whereas this effect could not be observed regarding liver metastases [53] . In support of this, Cejas et 74%) . Additionally, loss of oestrogen receptor expression in the pulmonary metastases is associated with a worse postmetastasectomy 5-year survival in these patients (77 vs 12%) [55] . Her2/neu expression status is also strongly associated with pulmonary-specific metastasis in osteosarcoma patients [49, 56, 57] . Her2/neu could be detected immunohistochemically in 32% of primary osteosarcomas and in 53% of corresponding pulmonary metastases. Moreover, Her2/neu correlated with early pulmonary spreading (17.2 vs 31.8 months), but did not affect the post-metastasectomy survival [45] . Zhou et al. [58] confirmed these results and provided additional evidence of c-erbB2 gene amplifications in some cases.
Expression of FOS-B and Ets-1.
Addressing the prognostic value of proto-oncogenes in pulmonary metastasectomy, Finkel-BiskisJinkins murine osteosarcoma viral oncogene homologue B (FOS-B), has been investigated. Initially, FOS-B has been associated with tumour progression in primary CRC [59] . When detected in pulmonary metastases of CRC, FOS-B significantly affected the recurrence-free survival as well as the overall survival in univariate analysis, although this could not be confirmed in multivariate analysis [60] . Ets-1, an oncoprotein and transcription factor involved in matrix degradation is expressed in tumour cells as well as in the tumoursurrounding stroma, facilitating tumour progression. The expression level in pulmonary metastases correlated with corresponding primary CRC. Furthermore, stromal expression of Ets-1 significantly and independently predicted pulmonary recurrence of primary CRC [61] . Evaluating the prognostic value of Ets-1 regarding the post-metastasectomy outcome was not an aim of this study.
Cell metabolism
Glucose processing. An altered cell metabolism is common in various cancerous tissues. It is necessary for a tumour to be provided with sufficient amounts of carbohydrates, proteins, lipids and nucleic acids in order to meet the increased demand. One of the most investigated metabolic phenotype in cancer is the excessive glucose uptake of tumour tissue, the so-called Warburg Continued effect [62] . Tumour cells generate adenosine triphosphate (ATP) to a high degree through aerobic glycolysis. Aerobic glycolysis is less efficient in generating ATP, therefore resulting in an increased glucose demand and consecutive uptake of glucose in tumour tissue. However, it has been speculated that aerobic glycolysis is superior to oxidative phosphorylation in hypoxic tumour tissue and leads to clonal selection of these cells [63] . The increased uptake of glucose via glucose transporters (GLUT) is also the basis for clinical tumour imaging by 18 [F]-fluorodeoxyglucose-positron emission tomography (FDG-PET). Hence, FDG uptake correlates with the expression of GLUT1 [64] . Kaira et al. published a work comparing 18 [F]-FDG uptake and histological markers associated with glucose metabolism in patients with either NSCLC or pulmonary metastases from extrapulmonary malignancy and a control group with benign nodules. A 18 [F]-FDG uptake beyond the calculated cut-off value was evident in 60, 29, 36, 44, 66, 66, 71 and 50% of pulmonary nodules of primary CRC (n = 80), sarcoma (n = 17), head and neck cancer (n = 14), breast cancer (n = 9), genital cancers (n = 12), oesophageal cancer (n = 3), gastrointestinal cancer (n = 7) and others (n = 4), respectively. Furthermore, 18 [F]-FDG uptake correlated with expression of GLUT1, hexokinase I, HIF-1alpha vascular endothelial growth factor (VEGF) and microvascular density in the pulmonary metastases and the size of the pulmonary nodules. The 5-year survival for all patients with confirmed metastases from an extrathoracic primary was 75.6 months. Assigning them to groups according the 18 [F]-FDG uptake, patients with highly positive pulmonary nodules were shown to have a significantly shorter median survival time. This finding was, however, limited by the fact that patients with different primary tumours were included in this analysis [65] . GLUT1 overexpression was also identified as a prognostic factor for poor overall survival after pulmonary metastasectomy in patients with primary melanoma. A potential correlation with 18 [F]-FDG uptake was not assessed in this work [34] . Further studies are needed to elucidate the glucose metabolism imaged by 18 [F]-FDG uptake as a prognostic tool. AFP: Alpha-fetoprotein; ASFC: aerogenous spread with floating cancer cell clusters; bcl-2: B-cell lymphoma 2; BRCA1: breast cancer susceptibility gene 1; CA: carbohydrate antigen; CD: cluster of differentiation; CEA: carcinoembryonic antigen; CEACAM: carcinomembryonic antigen-related cell-adhesion molecule 1 (CD66a); COX-2: cyclooxygenase 2; DCP: des-gamma-carboxy prothrombin; DFS: disease-free-survival; DPD: dihydropirimidine dehydrogenase; EGFR: epidermal growth factor receptor; ER: oestrogen receptor; ERCC1: excision repair cross-complementation group 1; FDG: 18F-fluorodeoxyglucose; FOS-B: Finkel-Biskis-Jinkins murine osteosarcoma viral oncogene homologue B; GLUT: glucose transporter; hCG: human chorionic gonadotropin; HER1/neu: human epidermal growth factor receptor 2/erb-B2; HIF-1: hypoxia-inducible factor 1; IGF1R: insulin-like growth factor 1 receptor; KRAS: Kirsten rat sarcoma viral oncogene homologue; LMFS: lung metastasis-free survival; MVD: microvessel density; n.s.: not significant; OPRT: orotate phosphoribosyltransferase; OS: 5-year overall survival; PCNA: proliferating cell nuclear antigen; PDGFR: platelet-derived growth factor receptor; PM: pulmonary metastasectomy; TS: thymidylate synthase; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor. CT: computed tomography; CXR: chest X-ray; FDG: 18F-fluorodeoxyglucose; GLUT1: glucose transporter 1; HIF-1: hypoxia-inducible factor 1; MVD: microvessel density; n.s.: not significant; OS: 5-year overall survival; PET: positron emission tomography; TDT: tumour doubling time; VEGF: vascular endothelial growth factor.
REVIEW
Predictive markers indicating chemoresistance. Another important aspect with regard to cell metabolism lies in the changes leading to resistance to chemotherapeutics. In patients with pulmonary dissemination receiving an inter-disciplinary treatment, surgical removal of lung metastases is often accompanied by adjuvant chemotherapy. For that reason, markers predicting the response of patients to cytotoxic agents might affect the prognosis after metastasectomy. In the following, we discuss interesting findings regarding predictive markers in patients with pulmonary metastases. Thymidylate synthase (TS) is an enzyme that is involved in the metabolism of 5-fluorouracil (5-FU), pemetrexed and raltitrexed. An increased expression level of TS in primary CRC has been described as predictive for 5-FU response and patients' prognosis. Jensen et al. [66] underlined the importance of differentiating between tumour tissues from the primary tumour site or the metastasis, as they possess divergent characteristics regarding their pattern of chemoresistance. Supporting this, an increased expression of TS was detected in the pulmonary metastases of primary CRC, compared with the corresponding primary tumour and/or liver metastases [67] [68] [69] . Patients with CRC receiving 5-FU-based adjuvant chemotherapy after pulmonary metastasectomy and sufficient expression of TS in lung metastases benefited most from adjuvant chemotherapy. In the same study, this could also been shown for other proteins, which are involved in chemoresistance (orotate phosphoribosyltransferase (OPRT), excision repair cross-complementation group 1 (ERCC1) and breast cancer susceptibility gene 1 (BRCA1)) [70] . In patients with primary osteosarcoma, the expression of P-glycoprotein is significantly increased in pulmonary metastases compared with the primary tumours [45] . P-glycoprotein is a product of the multidrug resistance gene 1 and mediates the resistance to doxorubicin [71] . Expression of P-glycoprotein in primary tumours or pulmonary metastases is not associated with recurrence-free survival or survival after metastasectomy [45] . Cyclooxygenase-2 (COX-2) is involved in metastasis and resistance to chemoradiotherapy, particularly in patients with osteosarcoma [72, 73] . Increased expression of COX-2 in lung metastases predicts a worse outcome of patients with primary osteosarcoma and lung metastases, whereas the expression level of COX-2 seems not to be capable to prognosticate the outcome [74, 75] . Therefore, COX-2 seems to be a valuable prognostic marker in the sub-population of patients undergoing pulmonary metastasectomy. In summary, existing data on the prognostic and predictive effect of cell metabolism markers is contradictory, and the contribution of these enzymes to the treatment outcome of patients with metastatic disease needs to be further elucidated.
Tumour angiogenesis
Sufficient blood supply is crucial for the growth of a tumour. Pivotal proangiogenetic mediators are VEGF, EGF, platelet-derived growth factor (PDGF) and their receptors (VEGFR, EGFR and EGFR, respectively) [76] . The increased activity of the proangiogenetic pathways leads to strongly vascularized tumours. This hypervascularization can be determined histologically and/or radiologically.
Receptor tyrosine kinases and ligands. The expression level of receptor tyrosine kinases has been described in various primary tumours and paired pulmonary metastases, irrespective of their potential role as biomarkers [77, 78] . An increased expression of VEGFα in pulmonary nodules compared with corresponding primary CRC could be determined by reverse transcription polymerase chain reaction [26] . Additionally, this increased expression of VEGF in CRC pulmonary metastases was found be an independent prognostic marker for poor 5-year survival in multivariate analysis (18 vs 46.1%) [79] . In metastatic osteosarcoma, the expression of VEGF in the metastatic lesion was comparable to that of the primary tumour. Nevertheless, the high expression level of VEGF in the primary tumour was associated with decreased survival in univariate analysis, whereas expression of VEGF in the metastatic lesion did not affect the outcome [33] . In a further work assessing pulmonary metastases from primary CRC, expression of VEGF-D, a VEGF sub-type that mediates lymphangiogenesis, was not associated with recurrence-free survival or overall survival [60] . Interestingly, VEGF expression was shown to correlate with 18 [F]-FDG uptake in pulmonary metastases from primary epithelial cancers [65] . This finding emphasizes the potential of PET-imaging to reflect tumour biology. Another growth factor involved in angiogenesis is the insulin-like growth factor. The increased expression of the corresponding receptor (IGF1R) seems not have prognostic value in metastatic CRC [21] .
Microvessel density. Microvessel density can be determined immunohistochemically by staining of e.g. CD31 or CD34 and calculating the number of vessels per area. Pulmonary metastases from primary CRC with low microvessel density are associated with better outcomes after pulmonary metastasectomy and 5-FU-based adjuvant chemotherapy, whereas this is unaffected by the expression of VEGF [70] . As mentioned above, microvessel density correlates with 18 [F]-FDG uptake in various tumours [65] . Hyper-vascularized pulmonary metastases from primary melanoma are associated with worse survival after pulmonary metastasectomy [34] .
CONCLUSION
Currently, the prognosis of cancer patients is based on the TNM classification. As this system is of limited value for patients undergoing pulmonary metastasectomy [4] , further prognostic markers are warranted. The most prominent literature on prognostic factors following pulmonary metastasectomy was published 1997, reviewing over 5000 data sets from the IRLM [3] . The risk factors described in this publication are solely based on clinical observations. However, these factors correspond to tumour aggressiveness, characterized by a rapid, invasive and diffuse pattern of metastasis (short disease-free interval, incomplete resection and number of nodules). Each molecular and radiological marker of our review can be linked to the tumour phenotype described by the IRLM. Two examples illustrate this relationship: E-cadherin expression and markers of tumour angiogenesis. A loss of the epithelial marker E-cadherin is a key factor in the process of a diffuse tumour spreading. It enables the disaggregation of cancer cells from one another, which is the first step of the metastatic cascade. Thus, E-cadherin expression may be directly linked to the number of nodules and the disease-free interval. Supporting this, decreased levels of E-cadherin are still evident in metastatic tissue. On the other hand, angiogenesis is considered an essential component of tumour metastasis. Most of the disseminated tumour cells undergo apoptosis or remain in a silenced state on the secondary site, because sufficient vascularization limits the outgrowth of micrometastases to clinically detectable macrometastases. Therefore, the up-regulation of TRK-pathways as described in this review may contribute to the number of metastasis-one of the IRLM risk factor for poor survival.
Methods in molecular biology and radiological imaging techniques have provided clinicians with a myriad of novel prognostic markers in cancer research. The majority of the findings reviewed here underline the divergent biology of primary tumour and corresponding pulmonary metastases. Compared with the existing literature on prognostic markers in primary tumours, only few studies have focused on the subset of patients with pulmonary metastases, which widely consists of a small series of highly selected patients. The best evidence for prognostic significance that is already clinically applicable are the findings on CEA ( premetastasectomy serum level ≥5 ng/ml) in patients with primary CRC. Detection of CEA is easy and reproducible by commercially available assays and has pioneered the use of novel biomarkers in pulmonary metastasectomy. Besides this promising serum marker, non-invasive methods in radiology/nuclear medicine, e.g. PET-CT might be an important prognostic tool in the future. All other suggested markers of this review are still in a preclinical or even experimental phase and therefore a transition to a clinical application is currently not possible. It is important to notice that identifying poor prognostic markers in patients with pulmonary metastases remains a desirable aim, but should not lead to an increase in the long-term survival of our patients solely by stronger patient selection. Rather than withholding surgery from patients with a putative poor prognosis, aggressive treatment regimens with a multidisciplinary approach should be applied, whereas in low-risk patients, cost-intensive and burdening treatment and surveillance strategies might be unnecessary.
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